MDL | MFCD31630816 |
---|---|
Molecular Weight | 458.18 |
Molecular Formula | C5H10Cl4N2ORuS.C3H4N2.H |
SMILES | Cl[Ru](Cl)(Cl)(Cl)(C)[N]1=CNC=C1.O=S(C)C.[-].[H+].C2=CNC=N2 |
NAMI-A is a ruthenium-based drug characterised by the selective activity against tumour metastases, inhibits the adhesion and migration. In vitro: NAMI-A can significantly affect tumor cells with metastatic ability. The half lifetime of NAMI-A elimination from the lungs is longer than for liver, kidney, and primary tumor. NAMI-A bound to collagen is active on tumor cells as shown in vitro by an invasion test, using a modified Boyden chamber and Matrigel, and it inhibits the matrix metallo-proteinases MMP-2 and MMP-9 at micromolar concentrations. [1] The ruthenium drug NAMI-A inhibits the adhesion and migration of colorectal cancer cells. NAMI-A decreases α5β1 integrin expression and FAK auto-phosphorylation on Tyr 397. [2] In vivo: The reference for NAMI-A is 35 mg/kg/day. [1]
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
H 2 O : 8.28 mg/mL ( 18.07 mM ; Need ultrasonic and warming)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.1825 mL | 10.9127 mL | 21.8255 mL |
5 mM | 0.4365 mL | 2.1825 mL | 4.3651 mL |
10 mM | 0.2183 mL | 1.0913 mL | 2.1825 mL |
Add each solvent one by one: PBS
Solubility: 6.67 mg/mL (14.56 mM); Clear solution; Need ultrasonic and warming and heat to 60°C